Work in Microbiology, AR&D, QA, QC, Production, F&D at Caplin Point Laboratories
Caplin Point Laboratories Ltd generate over US$50 million in revenue annually with a healthy bottom line. We have recently been selected by Forbes Asia magazine as one of the Top 200 best performing companies in Asia, for the second time in a row. Caplin is the only Pharma company in India to be selected in both 2014 and 2015. We have been manufacturing, exporting and distributing our products to Latin America and Africa for the last 16 years and we're already in the Top 5 exporters from India to Latin America over the last few years. We are currently holding over 2000 product licenses in these regions with another 490 in the pipeline. Our latest Injectable facility in Gummidipoondi, built with a budget of HOcr has been funded entirely from internal accruals. The injectable factory has been approved by European Union and Brazil, with US FDA inspection likely to take place by 2016 last quarter.
SeQuent is looking towards the future with courage and confidence, because of the critical role it can play to help make a difference in global economic progress and social wellbeing. Ever since inception in 2002 SeQuent has emerged as an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation) and Human health (API).
